Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. PP405 is still under evaluation for safety.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The user has been using finasteride, minoxidil, and a derma stamp for 3 months with significant improvement. They are now adding ketoconazole to their routine.

PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

The user has been using finasteride for 7 months and is inquiring about Thrive's hair serum, which contains redensyl, procapil, and anagain, seeking feedback from others who have used it.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

The user shared their positive 5-month results using finasteride, minoxidil, derma rolling, and supplements like biotin, zinc, iron, and vitamin C. They provided before and after photos and mentioned applying minoxidil even when derma rolling.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

A user shared their 5-month hair regrowth progress using 5% topical minoxidil daily, microneedling weekly, and ketoconazole shampoo twice a week. Some suggest adding finasteride to maintain results, while others commend the current regimen's effectiveness.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The conversation is a satirical discussion about using a dermaroller on the penis, with mentions of adding finasteride and doing exercises like cock pushups and planks. Some users joke about side effects and the absurdity of the topic.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

The conclusion of this conversation is that the user experienced hair regrowth and increased overall hair thickness after using dutasteride and derma pen treatments for 5 years. They did not experience any side effects.